An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).

ABSTRACT: Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. Though pNETs represent a rare and heterogeneous disease, recent approaches are being taken to better understand the molecular pathways involved in carcinogenesis. Consequently, new treatment strategies are now available and others still under investigation show promising results. However, some questions around how to approach patients with pNETs are still unresolved, such as what the best sequence of treatments we can offer to each of our patients in the clinic at any time of their disease would

SUBMITTER: Alonso-Gordoa T 

PROVIDER: S-EPMC4837935 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature